During a live event, Sara Nunnery, MD, MSCI, and participants discussed different chemotherapy agents that can be used with pembrolizumab in patients with metastatic triple-negative breast cancer.
Targeted Oncology Staff
Articles by Targeted Oncology Staff
Discover the latest oncology breakthroughs, including FDA approvals, promising trials, and advancements in cancer treatment strategies for improved patient outcomes.
During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.
During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell lymphoma.
During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.
During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.
Discover the latest breakthroughs in oncology, including FDA designations and promising therapies for ovarian, breast, head and neck, bladder, and renal cancers.
During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.
During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.
During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.
During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.
During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.
Discover the latest breakthroughs in oncology, including promising therapies for breast, lung, and bladder cancers, enhancing patient outcomes and hope.
During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.
During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ribociclib in N0 and N1 breast cancer.
During a live event, Christopher J. Ferreri, MD, discussed findings on dose and schedule modifications of talquetamab in relapsed/refractory multiple myeloma.
During a live event, Michael R. Bishop, MD, discussed a case of steroid-refractory GVHD and the efficacy and safety outcomes from the ROCKstar trial.
Discover the latest breakthroughs in oncology, including FDA approvals and promising therapies that offer hope for cancer patients and clinicians alike.
During a live event, Christopher J. Ferreri, MD, discussed early- and late-presenting adverse events associated with talquetamab in relapsed/refractory multiple myeloma
During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant therapy choices in breast cancer.
In separate, live events, Sandip P. Patel, MD; David P. Carbone, MD, PHD; and their event participants considered treatment options for a patient with metastatic non–small cell lung cancer.
During a live event, Nataliya Mar, MD, discussed a non–clear cell renal cell carcinoma trial of cabozantinib/nivolumab and how it compares to other combinations.
During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.
August 2025 marked a transformative month in oncology as the FDA accelerates approvals for innovative cancer therapies, enhancing treatment options for patients.
This week in oncology highlights breakthroughs in cancer diagnostics and therapies, offering new hope for patients with colorectal, brain, ovarian, and breast cancers.
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.
During a live event, Raajit K. Rampal, MD, PhD, discusses managing a patient with low-risk polycythemia vera.
During a live event, Taha Al-Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to allogeneic transplant.
During a live event, Michael R. Bishop, MD, discussed efficacy and safety outcomes from the AGAVE-201 trial.